Current and historical daily PE Ratio for Viracta Therapeutics Inc (
) from 2021 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Viracta Therapeutics stock (STU:RYIS) PE ratio as of Jun 20 2024 is 0.
More Details
Viracta Therapeutics Inc (STU:RYIS) PE Ratio (TTM) Chart
Viracta Therapeutics Inc (STU:RYIS) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 847
- 1
- 2
- 3
- 4
- 5
- 6
- 10
Viracta Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-20 | At Loss | 2024-04-17 | At Loss |
2024-06-19 | At Loss | 2024-04-16 | At Loss |
2024-06-18 | At Loss | 2024-04-15 | At Loss |
2024-06-17 | At Loss | 2024-04-12 | At Loss |
2024-06-14 | At Loss | 2024-04-11 | At Loss |
2024-06-13 | At Loss | 2024-04-10 | At Loss |
2024-06-12 | At Loss | 2024-04-09 | At Loss |
2024-06-11 | At Loss | 2024-04-08 | At Loss |
2024-06-10 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-03-28 | At Loss |
2024-06-03 | At Loss | 2024-03-27 | At Loss |
2024-05-31 | At Loss | 2024-03-26 | At Loss |
2024-05-30 | At Loss | 2024-03-25 | At Loss |
2024-05-29 | At Loss | 2024-03-22 | At Loss |
2024-05-28 | At Loss | 2024-03-21 | At Loss |
2024-05-27 | At Loss | 2024-03-20 | At Loss |
2024-05-24 | At Loss | 2024-03-19 | At Loss |
2024-05-23 | At Loss | 2024-03-18 | At Loss |
2024-05-22 | At Loss | 2024-03-15 | At Loss |
2024-05-21 | At Loss | 2024-03-14 | At Loss |
2024-05-20 | At Loss | 2024-03-13 | At Loss |
2024-05-17 | At Loss | 2024-03-12 | At Loss |
2024-05-16 | At Loss | 2024-03-11 | At Loss |
2024-05-15 | At Loss | 2024-03-08 | At Loss |
2024-05-14 | At Loss | 2024-03-07 | At Loss |
2024-05-13 | At Loss | 2024-03-06 | At Loss |
2024-05-10 | At Loss | 2024-03-05 | At Loss |
2024-05-09 | At Loss | 2024-03-04 | At Loss |
2024-05-08 | At Loss | 2024-03-01 | At Loss |
2024-05-07 | At Loss | 2024-02-29 | At Loss |
2024-05-06 | At Loss | 2024-02-28 | At Loss |
2024-05-03 | At Loss | 2024-02-27 | At Loss |
2024-05-02 | At Loss | 2024-02-26 | At Loss |
2024-04-30 | At Loss | 2024-02-23 | At Loss |
2024-04-29 | At Loss | 2024-02-22 | At Loss |
2024-04-26 | At Loss | 2024-02-21 | At Loss |
2024-04-25 | At Loss | 2024-02-20 | At Loss |
2024-04-24 | At Loss | 2024-02-19 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
Viracta Therapeutics Inc (STU:RYIS) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Viracta Therapeutics Inc Viracta Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000C29B.png?14)
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.